Cingulate Inc.
CING evidence brief
What we can confirm
- Market Cap:
- $73.0M
What it means
What to watch
Prepared research question
What matters most for CING—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CING
Cingulate Inc. (CING) is a biopharmaceutical company developing next-generation products using its proprietary Precision Timed Release (PTR) drug delivery platform, with a lead candidate CTx-1301 for ADHD undergoing CMC work toward NDA resubmission.
Key risk: No approved products
Market Cap
$73.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 clinical trials for Cingulate Inc..
Cingulate Inc. (CING) is a biopharmaceutical company developing next-generation products using its proprietary Precision Timed Release (PTR) drug delivery platform, with a lead candidate CTx-1301 for ADHD undergoing CMC work toward NDA resubmission.
- Cash and cash equivalents of $28.4 million as of June 30, 2026, expected to fund operations into mid-2027 [sec_mda · as of 2026-08-13].
- Net income of -$5.9M and shareholders' equity of $23.5M as of June 30, 2026 [sec].
- Lead product candidate CTx-1301 (for ADHD) is in CMC work for NDA resubmission, with Phase 3 results published in a peer-reviewed journal in July 2026 [news · published 2026-07-30].
- The company's PTR platform uses a proprietary Erosion Barrier Layer to enable once-daily, multi-dose tablets [sec_mda · as of 2026-08-13].
- Additional capital will be needed to advance other development programs beyond CTx-1301 [sec_mda · as of 2026-08-13].
What works
- Cash runway through mid-2027 provides time to complete CMC work and seek regulatory approval for CTx-1301 without near-term financing pressure [sec_mda · as of 2026-08-13].
- Phase 3 ADHD trial results for CTx-1301 were published in a peer-reviewed journal, supporting its efficacy and safety profile [news · published 2026-07-30].
- The PTR platform is designed to create differentiated once-daily multi-dose tablets, potentially improving patient compliance [sec_mda · as of 2026-08-13].
What to weigh
- The company has no approved products and has not yet generated revenue; ability to generate revenue depends on successful development and regulatory approval [sec_mda · as of 2026-08-13].
- Additional capital will be required to advance other development programs beyond CTx-1301, creating future funding uncertainty [sec_mda · as of 2026-08-13].
- Net loss of $5.9M for the quarter ended June 30, 2026, reflecting ongoing R&D and operational expenses without offsetting revenue [sec].
From the filings
Quoted directly from source documents.
Cash position and runway
“As of June 30, 2026, we had cash and cash equivalents of $28.4 million, which we believe will be sufficient to fund our operations into mid 2027”
SEC MD&A · August 13, 2026
Phase 3 results publication
“Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology”
News · July 30, 2026
PTR platform description
“Our PTR platform incorporates a proprietary Erosion Barrier Layer designed to allow for the release of drug substance at specific, pre-defined time intervals”
SEC MD&A · August 13, 2026
Need for additional capital
“We will need additional capital to advance other potential development programs.”
SEC MD&A · August 13, 2026
Risks & what to watch (3)›
Key risks
- No approved products — Company has no marketed products and no revenue; all future income depends on regulatory approval and commercialization [sec_mda · as of 2026-08-13].
- Funding gap for pipeline — Additional capital required to advance programs beyond CTx-1301; current runway only covers CTx-1301 work [sec_mda · as of 2026-08-13].
- CMC/regulatory delays — NDA resubmission for CTx-1301 depends on completing CMC work; any delays could extend timeline and increase costs [news · published 2026-08-13].
What to watch
- Completion of CMC work and NDA resubmission for CTx-1301 [news · published 2026-08-13].
- FDA feedback and regulatory decision on CTx-1301 [sec_mda · as of 2026-08-13].
- Cash burn rate and whether additional financing is raised before mid-2027 [sec_mda · as of 2026-08-13].
- Progress of CTx-2103 (buspirone for anxiety) toward clinical development [sec_mda · as of 2026-03-18].
Sources: News · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Cingulate Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cingulate Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 14.9%
- Days to cover
- 3.3
- Shares short
- 1,495,654
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CING short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cingulate Inc.?
Cingulate Inc. (CING) is a biopharmaceutical company developing next-generation products using its proprietary Precision Timed Release (PTR) drug delivery platform, with a lead candidate CTx-1301 for ADHD undergoing CMC work toward NDA resubmission.
Who is the CEO of Cingulate Inc.?
Dr. Shane J. Schaffer Pharm.D. is the chief executive officer of Cingulate Inc. (CING).
Where is Cingulate Inc. headquartered?
Cingulate Inc. (CING) is headquartered in Kansas City, KS, United States.
What therapeutic areas does Cingulate Inc. focus on?
Cingulate Inc. develops therapies across Oncology, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.